Teitur Trophics

Overview

Teitur Trophics is a biotechnology company focused on developing neurotrophic factor therapies for neurodegenerative diseases. The company's name is derived from Old Norse "teitr" (meaning "happy" or "joyful") and "trophic" (relating to growth and nutrition), reflecting its mission to restore neuronal health and function[@teitur].

Company Overview

| Attribute | Details |
|-----------|---------|
| Founded | ~2019 |
| Headquarters | USA |
| Focus | Neurotrophic factors, Alzheimer's disease, Parkinson's disease |
| Status | Private |
| Stage | Preclinical/Discovery |

Research Focus

Neurotrophic Factor Platform

Teitur Trophics specializes in:

• Brain-derived neurotrophic factor ([BDNF](/proteins/bdnf)) modulators — Enhancing BDNF signaling for synaptic protection
• Glial cell line-derived neurotrophic factor ([GDNF](/proteins/gdnf)) analogs — Supporting dopaminergic neuron survival
• Neuroprotective peptide development — Peptide-based neurotrophin mimetics
• Small molecule neurotrophin receptor agonists — Brain-penetrant small molecules targeting TrkB

Alzheimer's Disease Programs

The company is developing therapies targeting:

• Synaptic protection and regeneration — Preserving and restoring synaptic function
• Neuronal survival pathways — Activating pro-survival signaling
• Memory and cognitive function — Supporting memory formation and consolidation

Parkinson's Disease Programs

For PD, Teitur is focused on:

Overview

Teitur Trophics is a biotechnology company focused on developing neurotrophic factor therapies for neurodegenerative diseases. The company's name is derived from Old Norse "teitr" (meaning "happy" or "joyful") and "trophic" (relating to growth and nutrition), reflecting its mission to restore neuronal health and function[@teitur].

Company Overview

| Attribute | Details |
|-----------|---------|
| Founded | ~2019 |
| Headquarters | USA |
| Focus | Neurotrophic factors, Alzheimer's disease, Parkinson's disease |
| Status | Private |
| Stage | Preclinical/Discovery |

Research Focus

Neurotrophic Factor Platform

Teitur Trophics specializes in:

• Brain-derived neurotrophic factor ([BDNF](/proteins/bdnf)) modulators — Enhancing BDNF signaling for synaptic protection
• Glial cell line-derived neurotrophic factor ([GDNF](/proteins/gdnf)) analogs — Supporting dopaminergic neuron survival
• Neuroprotective peptide development — Peptide-based neurotrophin mimetics
• Small molecule neurotrophin receptor agonists — Brain-penetrant small molecules targeting TrkB

Alzheimer's Disease Programs

The company is developing therapies targeting:

• Synaptic protection and regeneration — Preserving and restoring synaptic function
• Neuronal survival pathways — Activating pro-survival signaling
• Memory and cognitive function — Supporting memory formation and consolidation

Parkinson's Disease Programs

For PD, Teitur is focused on:

• Dopaminergic neuron protection — Protecting substantia nigra neurons
• Neurotrophic support — Providing trophic support for dopaminergic pathways
• Disease-modifying approaches — Moving beyond symptomatic treatment

Pipeline

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| TT-101 | BDNF receptor agonist | Preclinical | Alzheimer's disease |
| TT-102 | GDNF analog | Discovery | Parkinson's disease |
| TT-103 | Neuroprotective peptide | Discovery | Neurodegeneration |

TT-101 (BDNF Receptor Agonist)

• Mechanism: Small molecule TrkB agonist
• Target: TrkB receptor (BDNF receptor)
• Phase: Preclinical
• Rationale: BDNF/TrkB signaling promotes synaptic plasticity and neuronal survival

TT-102 (GDNF Analog)

• Mechanism: GDNF receptor agonist
• Target: GFRα1/RET receptor complex
• Phase: Discovery
• Rationale: GDNF is a potent neurotrophic factor for dopaminergic neurons

Scientific Rationale

Why Neurotrophic Factors?

Neurotrophic factors are essential for neuronal survival and function:

BDNF in Neurodegeneration

[BDNF](/proteins/bdnf) (Brain-Derived Neurotrophic Factor):

• Critical for synaptic plasticity and memory
• Reduced in Alzheimer's disease brain
• TrkB activation promotes neuronal survival
• Small molecule agonists can cross BBB

GDNF in Parkinson's Disease

[GDNF](/proteins/gdnf) (Glial Cell Line-Derived Neurotrophic Factor):

• Potent survival factor for dopaminergic neurons
• Supports substantia nigra pars compacta neurons
• Clinical trials have shown promise
• Delivery challenges being addressed

Competitive Landscape

| Company | Drug | Mechanism | Stage |
|--------|------|-----------|-------|
| Athira Pharma | Fosgonimeton | HGF/MET agonist | Phase 2/3 |
| AbbVie | -- | TrkB agonist | Preclinical |
| Takeda | -- | GDNF analog | Preclinical |
| Neurogenerative | -- | GDNF | Discontinued |

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [BDNF](/proteins/bdnf)
• [GDNF](/proteins/gdnf)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [PD Pipeline Companies](/companies/pd-pipeline-companies)
• [Athira Pharma](/companies/athira-pharma)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References